QLS1522 / Qilu Pharma - LARVOL DELTA

Discovery of QLS1522, a mutant-selective allosteric PI3Kα inhibitor for the treatment of PIK3CA-mutant solid tumors (AACR 2026) - "While approved PI3Kα inhibitors like Alpelisib validate that PI3Kα blockade can suppress tumors and improve outcomes in PIK3CA-mutant ER+HER2- breast cancer, their major on-target toxicity against wild-type PI3Kα interferes with regulation of glucose metabolism which reduces their therapeutic index and limits clinical efficacy...Notably, it maintained selectivity comparable to STX-478 and better than RLY-2608 in wild-type SKBR3 cells... QLS1522 is a mutant-selective allosteric PI3Ka inhibitor and represents a promising therapeutic candidate for treating PIK3CA-mutant solid tumors. IND-enabling studies are currently in progress."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PIK3CA